Genprex

News

Genprex Announces Receipt of $2.5 Million in Cash from Recent Warrant Exercises

The exercised warrants include all warrants that have been issued to investors in the Company’s public financings to date and represent approximately 70% of the Company’s overall outstanding warrants.

Read More

Genprex strikes deal with MD Anderson Cancer Center, adds to momentum in cancer fight

Austin startup a ripe M&A target for big pharma, one expert says

Read More


Genprex Issues April 2020 Shareholder Letter

Company provides updates on recent regulatory, clinical, operational, and business developments

Read More

Genprex’s Response to COVID-19 and its Business Operations

At Genprex, the health and well-being of the communities we serve, including those with cancer and diabetes, is our top priority.

Read More

Genprex Appoints Shannon Inman as Vice President of Global Clinical Operations

Proven executive with clinical operations expertise to guide the Company’s clinical programs with gene therapies

Read More

In pharma, cancer is king

Inside the industry’s quest for its next crowning achievement in oncology.

Read More

Highlighting Genprex’s Medical Advisors on National Doctors’ Day

March 30 marks National Doctors’ Day, an annual holiday when we can all acknowledge and show appreciation for our physicians who help save lives everywhere.

Read More

Genprex Bolsters Board of Directors, Appoints Three Biotechnology and Healthcare Industry Leaders

These board additions will enhance the Company’s ability to execute on key corporate initiatives.

Read More

Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives

These seasoned industry professionals combined with the company’s newly strengthened balance sheet will drive key clinical programs.

Read More